ALGN vs. BIIB: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ALGN and BIIB, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
ALGN’s market capitalization stands at 14.27 billion USD, while BIIB’s is 19.47 billion USD, indicating their market valuations are broadly comparable.
ALGN’s beta of 1.64 points to significantly higher volatility compared to BIIB (beta: 0.15), suggesting ALGN has greater potential for both gains and losses relative to market movements.
| Symbol | ALGN | BIIB |
|---|---|---|
| Company Name | Align Technology, Inc. | Biogen Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Devices | Drug Manufacturers - General |
| CEO | Joseph M. Hogan | Christopher A. Viehbacher |
| Price | 196.82 USD | 132.87 USD |
| Market Cap | 14.27 billion USD | 19.47 billion USD |
| Beta | 1.64 | 0.15 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | January 30, 2001 | September 17, 1991 |
| ADR | No | No |
Historical Performance
This chart compares the performance of ALGN and BIIB by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
ALGN
10.67%
Medical - Devices Industry
- Max
- 49.04%
- Q3
- 9.53%
- Median
- -7.46%
- Q1
- -32.83%
- Min
- -82.64%
In the upper quartile for the Medical - Devices industry, ALGN’s Return on Equity of 10.67% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
BIIB
8.97%
Drug Manufacturers - General Industry
- Max
- 95.59%
- Q3
- 76.92%
- Median
- 30.71%
- Q1
- 8.97%
- Min
- -14.85%
BIIB’s Return on Equity of 8.97% is on par with the norm for the Drug Manufacturers - General industry, indicating its profitability relative to shareholder equity is typical for the sector.
Return on Invested Capital
ALGN
9.78%
Medical - Devices Industry
- Max
- 21.88%
- Q3
- 6.63%
- Median
- -1.11%
- Q1
- -21.08%
- Min
- -51.95%
In the upper quartile for the Medical - Devices industry, ALGN’s Return on Invested Capital of 9.78% signifies a highly effective use of its capital to generate profits when compared to its peers.
BIIB
7.84%
Drug Manufacturers - General Industry
- Max
- 25.72%
- Q3
- 17.89%
- Median
- 11.47%
- Q1
- 9.39%
- Min
- 2.87%
BIIB’s Return on Invested Capital of 7.84% is in the lower quartile for the Drug Manufacturers - General industry. This indicates a less efficient conversion of invested capital into profit compared to most of its competitors.
Net Profit Margin
ALGN
10.29%
Medical - Devices Industry
- Max
- 44.80%
- Q3
- 9.77%
- Median
- -5.53%
- Q1
- -29.37%
- Min
- -87.68%
A Net Profit Margin of 10.29% places ALGN in the upper quartile for the Medical - Devices industry, signifying strong profitability and more effective cost management than most of its peers.
BIIB
15.07%
Drug Manufacturers - General Industry
- Max
- 34.51%
- Q3
- 23.04%
- Median
- 14.73%
- Q1
- 11.78%
- Min
- 2.18%
BIIB’s Net Profit Margin of 15.07% is aligned with the median group of its peers in the Drug Manufacturers - General industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin
ALGN
14.69%
Medical - Devices Industry
- Max
- 30.13%
- Q3
- 13.12%
- Median
- 3.47%
- Q1
- -24.42%
- Min
- -80.56%
An Operating Profit Margin of 14.69% places ALGN in the upper quartile for the Medical - Devices industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
BIIB
23.17%
Drug Manufacturers - General Industry
- Max
- 40.70%
- Q3
- 28.90%
- Median
- 23.41%
- Q1
- 19.05%
- Min
- 16.13%
BIIB’s Operating Profit Margin of 23.17% is around the midpoint for the Drug Manufacturers - General industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | ALGN | BIIB |
|---|---|---|
| Return on Equity (TTM) | 10.67% | 8.97% |
| Return on Assets (TTM) | 6.71% | 5.28% |
| Return on Invested Capital (TTM) | 9.78% | 7.84% |
| Net Profit Margin (TTM) | 10.29% | 15.07% |
| Operating Profit Margin (TTM) | 14.69% | 23.17% |
| Gross Profit Margin (TTM) | 69.87% | 75.58% |
Financial Strength
Current Ratio
ALGN
1.21
Medical - Devices Industry
- Max
- 12.68
- Q3
- 6.30
- Median
- 4.05
- Q1
- 1.85
- Min
- 0.01
ALGN’s Current Ratio of 1.21 falls into the lower quartile for the Medical - Devices industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
BIIB
1.44
Drug Manufacturers - General Industry
- Max
- 1.67
- Q3
- 1.37
- Median
- 1.26
- Q1
- 0.87
- Min
- 0.39
BIIB’s Current Ratio of 1.44 is in the upper quartile for the Drug Manufacturers - General industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
Debt-to-Equity Ratio
ALGN
0.03
Medical - Devices Industry
- Max
- 2.34
- Q3
- 1.09
- Median
- 0.37
- Q1
- 0.08
- Min
- 0.00
Falling into the lower quartile for the Medical - Devices industry, ALGN’s Debt-to-Equity Ratio of 0.03 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
BIIB
0.39
Drug Manufacturers - General Industry
- Max
- 2.95
- Q3
- 2.44
- Median
- 0.86
- Q1
- 0.68
- Min
- 0.09
Falling into the lower quartile for the Drug Manufacturers - General industry, BIIB’s Debt-to-Equity Ratio of 0.39 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio
ALGN
--
Medical - Devices Industry
- Max
- 18.18
- Q3
- 7.53
- Median
- 0.85
- Q1
- -9.80
- Min
- -33.94
Interest Coverage Ratio data for ALGN is currently unavailable.
BIIB
9.43
Drug Manufacturers - General Industry
- Max
- 27.46
- Q3
- 14.40
- Median
- 7.80
- Q1
- 4.07
- Min
- 1.67
BIIB’s Interest Coverage Ratio of 9.43 is positioned comfortably within the norm for the Drug Manufacturers - General industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ALGN | BIIB |
|---|---|---|
| Current Ratio (TTM) | 1.21 | 1.44 |
| Quick Ratio (TTM) | 1.08 | 1.01 |
| Debt-to-Equity Ratio (TTM) | 0.03 | 0.39 |
| Debt-to-Asset Ratio (TTM) | 0.02 | 0.24 |
| Net Debt-to-EBITDA Ratio (TTM) | -0.94 | 1.49 |
| Interest Coverage Ratio (TTM) | -- | 9.43 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for ALGN and BIIB. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
ALGN
0.00%
Medical - Devices Industry
- Max
- 3.57%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALGN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
BIIB
0.00%
Drug Manufacturers - General Industry
- Max
- 8.72%
- Q3
- 4.10%
- Median
- 3.34%
- Q1
- 1.89%
- Min
- 0.00%
BIIB currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio
ALGN
0.00%
Medical - Devices Industry
- Max
- 102.12%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ALGN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
BIIB
0.00%
Drug Manufacturers - General Industry
- Max
- 266.46%
- Q3
- 78.91%
- Median
- 60.27%
- Q1
- 43.74%
- Min
- 0.00%
BIIB has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ALGN | BIIB |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio
ALGN
35.35
Medical - Devices Industry
- Max
- 90.56
- Q3
- 56.92
- Median
- 43.19
- Q1
- 21.79
- Min
- 5.55
ALGN’s P/E Ratio of 35.35 is within the middle range for the Medical - Devices industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
BIIB
13.12
Drug Manufacturers - General Industry
- Max
- 27.96
- Q3
- 25.84
- Median
- 18.32
- Q1
- 16.65
- Min
- 3.39
In the lower quartile for the Drug Manufacturers - General industry, BIIB’s P/E Ratio of 13.12 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Forward P/E to Growth Ratio
ALGN
3.34
Medical - Devices Industry
- Max
- 6.56
- Q3
- 3.52
- Median
- 2.22
- Q1
- 0.55
- Min
- 0.03
ALGN’s Forward PEG Ratio of 3.34 is within the middle range of its peers in the Medical - Devices industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
BIIB
3.21
Drug Manufacturers - General Industry
- Max
- 3.10
- Q3
- 3.09
- Median
- 2.72
- Q1
- 2.18
- Min
- 1.02
BIIB’s Forward PEG Ratio of 3.21 is exceptionally high for the Drug Manufacturers - General industry. This suggests its stock price is very high relative to its expected earnings growth, signaling significant overvaluation risk.
Price-to-Sales Ratio
ALGN
3.58
Medical - Devices Industry
- Max
- 15.74
- Q3
- 8.12
- Median
- 3.40
- Q1
- 2.37
- Min
- 0.42
ALGN’s P/S Ratio of 3.58 aligns with the market consensus for the Medical - Devices industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
BIIB
1.98
Drug Manufacturers - General Industry
- Max
- 6.47
- Q3
- 4.47
- Median
- 3.53
- Q1
- 1.96
- Min
- 0.41
BIIB’s P/S Ratio of 1.98 aligns with the market consensus for the Drug Manufacturers - General industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
ALGN
3.82
Medical - Devices Industry
- Max
- 16.65
- Q3
- 8.03
- Median
- 3.73
- Q1
- 1.92
- Min
- 0.65
ALGN’s P/B Ratio of 3.82 is within the conventional range for the Medical - Devices industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
BIIB
1.14
Drug Manufacturers - General Industry
- Max
- 7.80
- Q3
- 7.80
- Median
- 5.30
- Q1
- 4.06
- Min
- 1.08
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.
Valuation at a Glance
| Symbol | ALGN | BIIB |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 35.35 | 13.12 |
| Forward PEG Ratio (TTM) | 3.34 | 3.21 |
| Price-to-Sales Ratio (P/S, TTM) | 3.58 | 1.98 |
| Price-to-Book Ratio (P/B, TTM) | 3.82 | 1.14 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 22.62 | 8.48 |
| EV-to-EBITDA (TTM) | 16.80 | 8.69 |
| EV-to-Sales (TTM) | 3.39 | 2.39 |